Αναζήτηση Δραστικών

REMIFENTANIL

Εμπορικές Ονομασίες

  • ULTIVA
    Μορφές: PD.CSO.J.F
  • DRUGBANK - Remifentanil
  • indication:

    For use during the induction and maintenance of general anesthesia.

  • pharmacology:

  • mechanism:

    Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.

  • toxicity:

  • absorprion:

  • halflife:

    1-20 minutes

  • roouteelimination:

    Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.

  • volumedistribution:

    * 350 mL/kg * 452 ± 144 mL/kg [neonates] * 223 ± 30.6 mL/kg [adolescents]

  • clearance:

    * 40 mL/min/kg [young, healthy adults]